Results 21 to 30 of about 7,611 (182)

Secondary risks of bleeding and associated outcome after tirofiban application during interventional treatment of intracranial aneurysms. [PDF]

Brain Spine
Introduction Device-assisted endovascular treatment of ruptured aneurysms may require antiplatelet therapy, but bleeding risk is a concern. This retrospective propensity score-matched cohort study investigated whether tirofiban, including prolonged ...
Griessmair M, Bodden J, Hedderich DM, Kirschke J, Maegerlein C, Renz M, Platzek P, Meyer B, Zimmer C, Wostrack M, Boeckh-Behrens T, Schwarting J.   +11 more
europepmc   +2 more sources

Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. [PDF]

, 2022
Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation and is a potential adjunctive antithrombotic treatment in patients with acute coronary syndromes (ACS) or high-risk percutaneous coronary ...
Karathanos, Athanasios, Gurbel, Paul A., Nia, Amir M., Masyuk, Maryna, Kelm, Malte, Muessig, Johanna M., Nia, Amir M, Tantry, Udaya S, Jung, Christian, Muessig, Johanna M, Polzin, Amin, Gurbel, Paul A, Tantry, Udaya S., Heramvand, Nadia, Valgimigli, Marco   +14 more
core   +2 more sources

Efficacy and Safety of Tirofiban for the Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). [PDF]

Brain Behav
Graphical representation of the comparative efficacy and safety of intravenous tirofiban for acute ischemic stroke in randomized controlled trials. ABSTRACT Background: Tirofiban is a GP IIb/IIIa inhibitor, an anti‐platelet drug that is used in ischemic stroke or acute coronary syndromes.
Bullecer DL, Mohammed C, Loiola JAL, Chy MGT, Ramli SF, Hussein AS, Showkat WB, Taikadan T, Mutyala S, Ayyan M, Rehman MAU, Ahmad A, Alsubari AMA.   +12 more
europepmc   +2 more sources

Tirofiban for Branch Atheromatous Disease-Related Stroke: The STRATEGY Randomized Clinical Trial.

JAMA Neurol
Importance Patients with branch atheromatous disease (BAD)–related stroke are predisposed to early neurological deterioration (END) and disability. However, large-scale clinical trials focused on the prevention of
Wang Y, Liao X, Feng S, Pan Y, Wang X, Qu H, Liu Y, Gao C, Liu X, Yang Q, Zhang M, Liu Z, Ye J, Mao Y, Chen W, Jiang L, Bath PM, Johnston SC, Turc G, Zhao X, Wang Y, Wang Y, STRATEGY Investigators.   +22 more
europepmc   +2 more sources

Acute administration of tirofiban versus aspirin in emergent carotid artery stenting [PDF]

, 2019
BACKGROUND: Carotid artery stenting requires antiplatelet therapy for prevention of in-stent thrombosis. Patients suffering from acute ischemic stroke undergoing intravenous thrombolysis and emergent carotid artery stenting (eCAS) are at high risk for ...
Hlavica, Martin, Nedeltchev, Krassen, Gruber, Philipp, Diepers, Michael, Kahles, Timo, Berberat, Jatta, Remonda, Luca, Ineichen, Benjamin Victor   +7 more
core   +1 more source

The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis [PDF]

, 2021
BACKGROUND AND PURPOSE: The safety and efficacy of tirofiban during endovascular therapy in patients undergoing intravenous thrombolysis with recombinant IV tPA remain unclear.
Sohn, S.-I., Hong, J.M., Lee, J.S., Kim, YS, Hong, JM, Kim, Y.-S., Kang, DH, Hong, JH, Jang, SH, Kim, Y.-W., Hwang, YH, Hong, J.-H., Hwang, Y.-H., Choi, JW, Lee, SJ, Sohn, SI, Lee, S.-J., Jang, S.H., Kang, D.-H., Kim, C-H., Kim, YW, Park, H, Kim, CH, Choi, J.W., Park, H., Lee, JS   +25 more
core   +1 more source

Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion

BMC Neurology, 2022
Background Even undergoing mechanical thrombectomy (MT), patients with acute vertebrobasilar artery occlusion (AVBAO) still have a high rate of mortality.
Xiding Pan, Mengyi Xu, Yuxiang Fei, Shiteng Lin, Yapeng Lin, Jianjun Zou, Jie Yang   +6 more
doaj   +1 more source

Tirofiban provides “platelet anesthesia” during cardiopulmonary bypass in baboons [PDF]

, 1997
Objective: Tirofiban (Aggrastat) is a reversible, nonpeptide inhibitor of platelet glycoprotein II/IIIa receptors. We tested the hypothesis that tirofiban preserves platelet number and function and shortens postoperative bleeding times in baboons after ...
Gorman, Joseph H., Anderson, Harry L., Marcinkiewicz, Cezary, Gould, Robert J., Niewiarowski, Stefan, Edmunds, L.Henry, Hiramatsu, Yuji, Gikakis, Nicolas   +7 more
core   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +2 more sources

The Safety and Efficiency of Tirofiban in Acute Ischemic Stroke Patients Treated with Mechanical Thrombectomy: A Multicenter Retrospective Cohort Study

Biochemistry Research International, 2020
Introduction. Limited comparative studies have reported the safety and efficacy of tirofiban in acute ischemic stroke (AIS) patients after mechanical thrombectomy (MT).
Lili Zhao, Yating Jian, Tao Li, Heying Wang, Zhang Lei, Man Sun, Ye Li, Yiheng Zhang, Meijuan Dang, Wang Huqing, Sun Hong, Zhang Ru, Hongxing Zhang, Yi Jia, Luo Guogang, Zhang Guilian   +15 more
doaj   +1 more source